A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 344 participants.
Also called NCT04955834
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 344 participants
- Registry
-
NCT04955834
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04955834. Randomized; no masking; primary purpose treatment. Start 2021-07-27 (actual); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Insulin degludec injection
- Intervention (Drug)
- Tresiba®
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Record details
- Record id
cardio:ct-nct04955834- Content hash
1b40fd6c7064f2eec18dfd9717ba790bf6639e60ec37d91ae2b5f216d78178af